Cowen

Salomon Brothers Alumni Rally for Historic Encore

Retrieved on: 
Friday, March 4, 2022
Cravath, Kidder, Peabody & Co., MBA, Salomon, Salomon Brothers, GCA, University, Bloomberg News, Citigroup, Bloomberg Industry Group, Goldman Sachs, Wall Street, Company, Industrial group, Cowen, Harvard Business School, Bank, Citigroup Global Markets Japan, Bank of America, GCA Corporation, JD, GLOBE, Cravath, Swaine & Moore, Clockmaker, New York University, LinkedIn

All three are alumni of Salomon Brothers who each spent decades at the legendary firm.

Key Points: 
  • All three are alumni of Salomon Brothers who each spent decades at the legendary firm.
  • Salomon Encore has struck a chord with alumni of Salomon Brothers with an outpouring of support ever since it announced the re-emergence of Salomon Brothers at the beginning of 2022.
  • There are an estimated 7,000 alumni of Salomon Brothers and over 500 have joined the Salomon community on Linkedin.
  • Salomon Encore is the modern Salomon Brothers.

CytoImmune Therapeutics to Participate in the Cowen's 42nd Annual Health Care Conference

Retrieved on: 
Thursday, March 3, 2022
Patient, Virus, Twitter, Bicycle, LinkedIn, Therapy, CA, Cancer, Conference, Cowen, Cell, Engineering, CAR, Immune system, GLOBE, Pharmaceutical industry, Vaccine

MONROVIA, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- CytoImmune Therapeutics , a clinical-stage cell-therapy company developing a novel class of tumor-reactive engineered natural killer cell-based cancer immunotherapies, today announced that the executive management team will participate in the Cowen's 42nd Annual Health Care Conference and host meetings with investors between March 7 and March 9, 2022.

Key Points: 
  • MONROVIA, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- CytoImmune Therapeutics , a clinical-stage cell-therapy company developing a novel class of tumor-reactive engineered natural killer cell-based cancer immunotherapies, today announced that the executive management team will participate in the Cowen's 42nd Annual Health Care Conference and host meetings with investors between March 7 and March 9, 2022.
  • Founded in 2017, CytoImmune Therapeutics is a clinical-stage biotechnology company, developing a novel class of cancer immunotherapy medicines based on engineered, allogeneic, tumor-reactive natural killer (TRACK-NKTM) cell therapies for patients with cancer.
  • The cells are engineered to both directly attack cancer cells and broadly stimulate both the innate and adaptive arms of the immune system through potent IL-15 secretion.
  • The company is headquartered in Monrovia, CA, with the fully functional manufacturing facility for cells and viruses in Puerto Rico.

Median Technologies to Participate in the Cowen’s 42nd Annual Health Care Conference

Retrieved on: 
Tuesday, March 1, 2022
Technology, Medical Devices, Other Technology, Software, Biotechnology, Radiology, Health, Data Management, Oncology, Diagnosis, BPI, Patient, Research, View, Investor, Lists of diseases, Cowen Inc., Cave rescue, Solution, Artificial intelligence, Cancer, Conference, Technology, SME, Cowen

Median Technologies (Paris: ALMDT), will be participating in the Cowens 42nd Annual Health Care Conference, taking place virtually on March 7-9, 2022.

Key Points: 
  • Median Technologies (Paris: ALMDT), will be participating in the Cowens 42nd Annual Health Care Conference, taking place virtually on March 7-9, 2022.
  • The live presentation will be available here and the replay will be posted on the Investors section of the Median Technologies website.
  • Cowens 42nd Annual Health Care Conference incorporates presentations, fireside chats and innovative panel discussions hosted by members of the Cowen research team that focus on various aspects of the health care industry.
  • About Median Technologies: About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.

Enovix to Participate in Cowen 2nd Annual Mobility Disruption Conference

Retrieved on: 
Tuesday, March 1, 2022
Lithium, GLOBE, Conference, Technology, News, Webcast, Mobility, Cowen, Video game

FREMONT, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Enovix Corporation (Enovix) (Nasdaq: ENVX), the leader in the design and manufacture of next generation 3D Silicon Lithium-ion batteries, today announced its participation in the virtual Cowen 2nd Annual Mobility Disruption Conference.

Key Points: 
  • FREMONT, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Enovix Corporation (Enovix) (Nasdaq: ENVX), the leader in the design and manufacture of next generation 3D Silicon Lithium-ion batteries, today announced its participation in the virtual Cowen 2nd Annual Mobility Disruption Conference.
  • Portfolio managers and analysts who wish to request a meeting should contact your respective sales representative at Cowen.
  • Cowens 2nd Annual Mobility Disruption Conference is a virtual event taking place March 2 - 4, 2022.
  • The conference incorporates fireside chats hosted by members of the Cowen research team exploring the technology enabled transitions underway in the Mobility sector.

Ikena Oncology to Participate in Cowen 42nd Annual Health Care Conference

Retrieved on: 
Tuesday, March 1, 2022
GLOBE, Investor, RAS, Twitter, ERK5, Company, Bristol Myers Squibb, LinkedIn, Hippopotamus, Cancer, Conference, Tumor microenvironment, TEAD, Program, Cowen, Pharmaceutical industry

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that management will be participating in the Targeted Oncology Panel at the Cowen & Co 42nd Annual Health Care Conference, taking place March 7-9, 2022.

Key Points: 
  • BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that management will be participating in the Targeted Oncology Panel at the Cowen & Co 42nd Annual Health Care Conference, taking place March 7-9, 2022.
  • The Company will also be holding investor meetings at the conference.
  • The presentation webcast can also be accessed by visiting the Investors & Media section of the companys website at www.ikenaoncology.com .
  • Ikena Oncology is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer.

Pico Announces Appointment of Ann Neidenbach to Board of Directors

Retrieved on: 
Monday, February 28, 2022
GLOBE, Italian Bourse, Board of directors, Connectivity, London Stock Exchange Group, Board, Syracuse, MTS, Group, Information system, Cowen, Organization, London Stock Exchange, BS, Telemetry, Founder CEO, Freedom, Corvil, Surat Diamond Bourse, Risk management, Capital market, CIO, LSEG, Nasdaq, Technology, Martin J. Whitman School of Management, CEO, Software, London, Management, Security (finance), Turquoise, Citigroup

NEW YORK, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Pico , a leading provider of mission critical technology, software, data and analytic services for the financial markets community, today announced the appointment of Ann Neidenbach to its Board of Directors effective immediately.

Key Points: 
  • NEW YORK, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Pico , a leading provider of mission critical technology, software, data and analytic services for the financial markets community, today announced the appointment of Ann Neidenbach to its Board of Directors effective immediately.
  • Ms. Neidenbach brings over three decades of experience as a technology executive at leading global financial services organizations.
  • Prior to her tenure at LSEG, Ms. Neidenbach held senior technology roles at Cowen, BNY Convergex, Nasdaq and Citi.
  • Pico provides a best-in-class portfolio of innovative, transparent, low-latency markets solutions coupled with an agile and expert service delivery model.

Chimerix to Present at Cowen and Company 42nd Annual Health Care Conference

Retrieved on: 
Monday, February 28, 2022
GLOBE, Smallpox, Regulation of tobacco by the U.S. Food and Drug Administration, Chief business officer, ONC201, NASDAQ, Company, Investor relations, Food, Sodium, Acute myeloid leukemia, Conference, Patient, Cowen, Pharmaceutical industry

An audio webcast of the fireside chat will be available on the Investor Relations section ofChimerix'swebsite at ir.chimerix.com , where it will be archived for approximately 90 days.

Key Points: 
  • An audio webcast of the fireside chat will be available on the Investor Relations section ofChimerix'swebsite at ir.chimerix.com , where it will be archived for approximately 90 days.
  • Chimerix is a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases.
  • In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure.
  • The Company has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT).

Adverum Biotechnologies to Participate in the 42nd Annual Cowen Healthcare Conference

Retrieved on: 
Monday, February 28, 2022
GLOBE, Adverum Biotechnologies, Investor, Webcast, Neovascularization, Degenerative disease, Auditory, Cowen Inc., Nasdaq, Conference, Patient, Research, Cowen, Eye, Pharmaceutical industry

REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in the Auditory and Ophthalmology panel discussion at the 42nd Annual Cowen Healthcare Conference on Monday, March 7, 2022, at 2:10 p.m.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in the Auditory and Ophthalmology panel discussion at the 42nd Annual Cowen Healthcare Conference on Monday, March 7, 2022, at 2:10 p.m.
  • Cowens 42nd Annual Health Care Conference is taking place virtually on March 7 - 9, 2022.The conference incorporates presentations, fireside chats and innovative panel discussions hosted by members of the Cowen research team that focus on various aspects of the health care industry.
  • Cowen Inc. (Cowen) is a diversified financial services firm that operates through two business segments: a broker dealer and an investment management division.
  • Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases.

Cabaletta Bio to Participate in the Cowen Virtual 42nd Annual Health Care Conference

Retrieved on: 
Monday, February 28, 2022
GLOBE, Glomerulonephritis, Neuromuscular junction, Degenerative disease, News, Webcast, Pemphigus, Haemophilia, MuSK protein, LinkedIn, Conference, Patient, Cowen, Pharmaceutical industry

PHILADELPHIA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in the Neuromuscular corporate panel discussion at the Cowen Virtual 42nd Annual Health Care Conference on Monday, March 7, 2022, at 9:10 a.m.

Key Points: 
  • PHILADELPHIA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in the Neuromuscular corporate panel discussion at the Cowen Virtual 42nd Annual Health Care Conference on Monday, March 7, 2022, at 9:10 a.m.
  • A live webcast of the panel will be available on the News and Events section of the Companys website at www.cabalettabio.com .
  • Replays of the webcast will be available on the website for 30 days.
  • Cabaletta Bios headquarters are located in Philadelphia, PA. For more information, visit www.cabalettabio.com and follow us on LinkedIn.

Jounce Therapeutics to Participate in Cowen & Co. 42nd Annual Health Care Conference

Retrieved on: 
Monday, February 28, 2022
GLOBE, Investor, LILRB2, ICOS, NASDAQ, Immune system, ILT4, PD-1, Therapy, Gilead Sciences, SELECT, Cancer, Conference, Patient, CCR8, Macrophage, Tumor microenvironment, Cowen, Pharmaceutical industry, Fourth, fifth, and sixth derivatives of position

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a novel immuno-oncology panel discussion at the Cowen & Co. 42nd Annual Health Care Conference on Monday, March 7, 2022 at 10:30 a.m.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a novel immuno-oncology panel discussion at the Cowen & Co. 42nd Annual Health Care Conference on Monday, March 7, 2022 at 10:30 a.m.
  • A webcast of the panel will be available by visiting Events and Presentations in the Investors and Media section of Jounces website at www.jouncetx.com .
  • Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform.
  • Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounces broader pipeline.